Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level.
波士顿，2024年7月31日 /PRNewswire/--最近，上海美迪西隆有限公司（“美迪西隆”）和江苏恒瑞医药有限公司（“恒瑞制药”）达成了战略合作协议。合作工作将侧重于新药模式的临床前评估，尤其是ADC、小核酸和CgT（细胞和基因疗法）药物。这种伙伴关系的目标是推动中国制药行业的创新，以在国际层面上竞争。
The elevated commitment to collaboration between Medicilon and Hengrui Pharma builds upon the solid foundation from years of experience and well-established trust. The organizations plan to integrate Medicilon's preclinical R&D expertise with Hengrui Pharma's innovative strategies and market influence. Medicilon will leverage its technological advantages in drug discovery and development to provide Hengrui Pharma with a range of preclinical services, focusing on efficacy testing, pharmacokinetics, and toxicology studies for new drug modalities. Medicilon and Hengrui Pharma will combine efforts to generate breakthroughs in pharmaceutical therapies.
美迪西隆和恒瑞制药对合作的更高承诺建立在多年的经验和牢固的信任基础之上。这些组织计划将美迪西隆的临床前研发专业知识与恒瑞制药的创新战略和市场影响力相结合。美迪西隆将利用其在药物发现和开发方面的技术优势，为恒瑞制药提供一系列临床前服务，重点是新药模式的疗效测试、药代动力学和毒理学研究。美迪西隆和恒瑞制药将共同努力，在药物疗法方面取得突破。
The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members.
交流的气氛热情友好。恒瑞制药副总经理兼全球研发总裁张连山以及其他高管参观了美迪西隆的浦东川沙公园。他们受到了美第奇隆首席执行官陈春林和主要团队成员的欢迎。
During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT.
访问期间，美第奇隆的研发团队介绍了其药物研发的一站式临床前服务平台，他们重点介绍了美迪西隆在安全性评估、药理学和药代动力学方面的能力和技术优势，特别关注PROTAC、ADC、核酸、双特异性抗体、肽、疫苗和cGT。
Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang stated, "Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning."
恒瑞制药副总经理兼全球研发总裁张连山表示：“Medicilon在该领域拥有强大的创新能力和服务质量，使其成为值得信赖的CRO合作伙伴。恒瑞制药与美迪西隆之间的合作不仅认可了过去的成就，而且代表了对未来合作潜力和前瞻性战略规划的深入探索。”
Medicilon's Founder & CEO Chunlin Chen stated, "Medicilon and Hengrui Pharma firmly believe that, through close collaboration, the process of drug R&D will be accelerated in the future, contributing to the innovative development of the global pharmaceutical industry."
美迪西隆创始人兼首席执行官陈春林表示：“美迪西隆和恒瑞制药坚信，通过密切合作，未来药物研发进程将得到加速，为全球制药行业的创新发展做出贡献。”
Website:
网站：
SOURCE Medicilon Inc.
来源 Medicilon Inc.